Skip to main content
Top
Published in: Internal and Emergency Medicine 6/2011

01-12-2011 | EM - ORIGINAL

Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department

Authors: Jiun-Nong Lin, Yen-Hsu Chen, Lin-Li Chang, Chung-Hsu Lai, Hsing-Lin Lin, Hsi-Hsun Lin

Published in: Internal and Emergency Medicine | Issue 6/2011

Login to get access

Abstract

Extended-spectrum β-lactamase (ESBL)-producing bacteria have been spreading from hospitals to communities. Despite this, there are limited emergency department (ED) patient-based studies about these bacteremias. A retrospective matched case–control study with a ratio of 1:3 was conducted at a university hospital. The case group consisted of patients aged >16 years with ESBL-producing bacteremias in the ED. Patients matched for age and sex with non-ESBL-producing bacteremias were sampled as the control group. Finally, 64 episodes of ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis bacteremias were included in our study. The median age of case patients was 71 years, and 29 (45.3%) were males. The most common type of infection was urinary tract infection (71.9%), followed by intra-abdominal infection (12.5%). Inappropriate empirical antibiotics therapy was prescribed in 87.5% of case patients, which was significantly higher than the control group (13.0%; p < 0.001). Patients with inappropriate empirical antibiotics had a significantly longer hospital stay than those with appropriate empirical antibiotics (p < 0.001). Multivariate analysis showed that hospital-acquired infection, urinary catheterization, and previous antibiotics use were independent risk factors for the acquisition of ESBL-producing bacteremia. The 28-day mortality rate of case patients was 18.8%. Whether they received appropriate empirical antibiotics treatment or not, there was no statistical difference in the mortality of patients with ESBL-producing bacteremias (p = 0.167). To face these emerging multidrug-resistant bacteria and to guide the empirical antibiotics therapy, it is crucial for emergency physicians to recognize the characteristics and risk factors for ESBL-producing organisms.
Literature
1.
go back to reference McCaig LF, McDonald LC, Cohen AL et al (2007) Increasing blood culture use at US hospital emergency department visits, 2001 to 2004. Ann Emerg Med 50:42–48PubMedCrossRef McCaig LF, McDonald LC, Cohen AL et al (2007) Increasing blood culture use at US hospital emergency department visits, 2001 to 2004. Ann Emerg Med 50:42–48PubMedCrossRef
2.
go back to reference Javaloyas M, Garcia-Somoza D, Gudiol F (2002) Epidemiology and prognosis of bacteremia: a 10-yr study in a community hospital. Scand J Infect Dis 34:436–441PubMedCrossRef Javaloyas M, Garcia-Somoza D, Gudiol F (2002) Epidemiology and prognosis of bacteremia: a 10-yr study in a community hospital. Scand J Infect Dis 34:436–441PubMedCrossRef
3.
go back to reference Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12PubMedCrossRef Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12PubMedCrossRef
4.
go back to reference Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36(Suppl 1):S11–S23PubMedCrossRef Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36(Suppl 1):S11–S23PubMedCrossRef
5.
go back to reference Pitout JDD, Nordmann P, Laupland KB et al (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59PubMedCrossRef Pitout JDD, Nordmann P, Laupland KB et al (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59PubMedCrossRef
6.
go back to reference Falagas ME, Karageorgopoulos DE (2009) Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 73:345–354PubMedCrossRef Falagas ME, Karageorgopoulos DE (2009) Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 73:345–354PubMedCrossRef
7.
go back to reference Rodríguez-Baño J, Picón E, Gijón P et al (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:40–48PubMedCrossRef Rodríguez-Baño J, Picón E, Gijón P et al (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:40–48PubMedCrossRef
8.
go back to reference Rodríguez-Baño J, Alcalá JC, Cisneros JM et al (2008) Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168:1897–1902PubMedCrossRef Rodríguez-Baño J, Alcalá JC, Cisneros JM et al (2008) Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168:1897–1902PubMedCrossRef
9.
go back to reference Rodríguez-Baño J, Navarro MD, Ngugro MD (2008) Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 14(Suppl 1):104–110PubMedCrossRef Rodríguez-Baño J, Navarro MD, Ngugro MD (2008) Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 14(Suppl 1):104–110PubMedCrossRef
10.
go back to reference Pitout JDD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166PubMedCrossRef Pitout JDD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166PubMedCrossRef
11.
go back to reference Cuevas O, Cercenado E, Gimeno M et al (2010) Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis 67:251–260PubMedCrossRef Cuevas O, Cercenado E, Gimeno M et al (2010) Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis 67:251–260PubMedCrossRef
12.
go back to reference Lin JN, Tsai YS, Lai CH et al (2009) Risk factors for mortality of bacteremic patients in the emergency department. Acad Emerg Med 16:749–755PubMedCrossRef Lin JN, Tsai YS, Lai CH et al (2009) Risk factors for mortality of bacteremic patients in the emergency department. Acad Emerg Med 16:749–755PubMedCrossRef
13.
go back to reference Burgess DS, Hall RG, Lewis JS et al (2003) Clinical and microbiologic analysis of a hospital’s extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23:1232–1237PubMedCrossRef Burgess DS, Hall RG, Lewis JS et al (2003) Clinical and microbiologic analysis of a hospital’s extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23:1232–1237PubMedCrossRef
14.
go back to reference Lee CH, Su LH, Tang YF et al (2006) Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58:1074–1077PubMedCrossRef Lee CH, Su LH, Tang YF et al (2006) Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58:1074–1077PubMedCrossRef
15.
go back to reference Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686PubMedCrossRef Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686PubMedCrossRef
16.
go back to reference Musikatavorn K, Chumpengpan C, Sujinpram C (2011) Risk factors of extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia in Thai emergency department: a retrospective case–control study. Asian Biomed 5:129–138 Musikatavorn K, Chumpengpan C, Sujinpram C (2011) Risk factors of extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia in Thai emergency department: a retrospective case–control study. Asian Biomed 5:129–138
17.
go back to reference Weinstein MP (2003) Blood culture contamination: persisting problems and partial progress. J Clin Microbiol 41:2275–2278PubMedCrossRef Weinstein MP (2003) Blood culture contamination: persisting problems and partial progress. J Clin Microbiol 41:2275–2278PubMedCrossRef
18.
go back to reference Clinical and Laboratory Standards Institute (2005–2009) Performance Standards for Antimicrobial Susceptibility Testing, 15th–19th informational supplements, document M100-S15-19. Wayne, PA Clinical and Laboratory Standards Institute (2005–2009) Performance Standards for Antimicrobial Susceptibility Testing, 15th–19th informational supplements, document M100-S15-19. Wayne, PA
19.
go back to reference Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538PubMed Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538PubMed
20.
go back to reference Kaye KS, Friedman ND, Stout JE et al (2002) Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–797PubMed Kaye KS, Friedman ND, Stout JE et al (2002) Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–797PubMed
21.
go back to reference Kang CI, Cheong HS, Chung DR et al (2008) Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 27:85–88PubMedCrossRef Kang CI, Cheong HS, Chung DR et al (2008) Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 27:85–88PubMedCrossRef
22.
go back to reference Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63:568–574PubMedCrossRef Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63:568–574PubMedCrossRef
23.
go back to reference Lautenbach E, Patel JB, Bilker WB et al (2001) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32:1162–1171PubMedCrossRef Lautenbach E, Patel JB, Bilker WB et al (2001) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32:1162–1171PubMedCrossRef
24.
go back to reference Kuster SP, Hasse B, Huebner V et al (2010) Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection 38:33–40PubMedCrossRef Kuster SP, Hasse B, Huebner V et al (2010) Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection 38:33–40PubMedCrossRef
25.
go back to reference Tumbarello M, Spanu T, Sanguinetti M et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:498–504PubMedCrossRef Tumbarello M, Spanu T, Sanguinetti M et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:498–504PubMedCrossRef
26.
go back to reference Kang C, Kim S, Kim DM et al (2004) Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25:860–867PubMedCrossRef Kang C, Kim S, Kim DM et al (2004) Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25:860–867PubMedCrossRef
27.
go back to reference Pitout JDD, Church DL, Hanson ND et al (2004) Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 38:1736–1741PubMedCrossRef Pitout JDD, Church DL, Hanson ND et al (2004) Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 38:1736–1741PubMedCrossRef
28.
go back to reference Kumar A, Ellis P, Arabi Y et al (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–1248PubMedCrossRef Kumar A, Ellis P, Arabi Y et al (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–1248PubMedCrossRef
29.
go back to reference Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef
30.
go back to reference Tumbarello M, Sanguinetti M, Montuori E et al (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994PubMedCrossRef Tumbarello M, Sanguinetti M, Montuori E et al (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994PubMedCrossRef
Metadata
Title
Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department
Authors
Jiun-Nong Lin
Yen-Hsu Chen
Lin-Li Chang
Chung-Hsu Lai
Hsing-Lin Lin
Hsi-Hsun Lin
Publication date
01-12-2011
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 6/2011
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-011-0707-3

Other articles of this Issue 6/2011

Internal and Emergency Medicine 6/2011 Go to the issue

CE - MEDICAL ILLUSTRATION

Systemic cysticercosis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.